Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/4/2026 | $6.00 | Buy | H.C. Wainwright |
| 3/12/2025 | $15.00 | Buy | B. Riley Securities |
6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)
6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)
6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)
First RECIST-confirmed durable Partial Response at current highest dose level #3 (90mCi) with the patient remaining progression free beyond seven months Second patient dosed remains progression free on treatment with RAD204 with early tumor shrinkage observed after first treatment RAD204 is generally well-tolerated with no dose-limiting toxicities observed in any of the dosing cohorts thus far SYDNEY and MALVERN, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced
RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint. 14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14) Sensitivity (secondary objective). Specificity data will be available in Q4 2026. The Company plans to advance RAD101 into a U.S. Phase 3 pivotal trial in Q4 2026 The imaging Brain Metastases total addressable market is ~$600+m for which there is no currently approved PET product SYDNEY, July 22, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiop
Issued on behalf of GT Biopharma, Inc. From bispecific ADCs at IDEAYA to a GSK partnership at Summit, B7-H3 has become one of the most actively pursued antigens in solid tumor oncology — and a new natural killer cell engager just entered the clinic SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody could quite figure out how to hit. The protein is broadly overexpressed across some of the most common — and most lethal — solid tumors, including prostate, lung, breast, ovarian, head and neck, and pancreatic cancers. It is largely absent from healthy ti
H.C. Wainwright initiated coverage of Radiopharm Theranostics with a rating of Buy and set a new price target of $6.00
B. Riley Securities initiated coverage of Radiance Medical with a rating of Buy and set a new price target of $15.00
3 - Radiopharm Theranostics Ltd (0001949257) (Issuer)
3 - Radiopharm Theranostics Ltd (0001949257) (Issuer)
3 - Radiopharm Theranostics Ltd (0001949257) (Issuer)
SYDNEY, July 22, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the appointment of Dr Oliver Sartor, MD to the Company's Scientific Advisory Board (SAB). Dr Sartor is an internationally recognised medical oncologist and scientist specialising in prostate cancer and radiopharmaceutical therapies. He currently serves as Director of Radiopharmaceutical Clinical Trials and Chair of the Genitourinary Cancer Disease Group at the world-renowned Mayo Clinic, in Rochester, Minnesota. He w